Angelin Utami Cahyani1, Eko Budiono2
1Resident ofInternal Medicine Departement of UGM Medical Faculty/Dr. Sardjito Hospital Yogyakarta
2Pulmonology Division of internal Medicine Departement of UGM Medical Faculty/Dr. Sardjito Hospital Yogyakarta
1Departemen Ilmu Penyakit Dalam FKUNSRI/RSMH Palembang
2Divisi Pulmonologi Departemen Ilmu Penyakit Dalam FKUNSRI/RSMH Palembang

Abstract
The found of Epidermal Growth Factor Receptor (EGFR)mutation in patient with Non Small Cell Lung Carcinoma (NSCLC) began the personalized therapy in treatment management of NSCLC. Since discovered 10 years ago, EGFR mutation which was response to Tyrosine Kinase Inhibitor (TKI) such asgefitinib, there was also found that the condition in which that therapy was resisted. Mutation in exon 20 insertion that leads to poor signaling of EGFR inhibition is associate with oncogenic trasnformation which is resistance to TKI. This case will be disscused to know if there is any resistance to TKI that need to be treated by other strategy.
Keywords: Lung Cancer, Non Small Cell Lung Carcinoma, Adenocarcinoma, Epidermal Growth Factor Receptor, Tyrosine Kinase Inhibitor, Gefitinib, Iressa